A Phase II Trial of Oxaliplatin and Trastuzumab in the Treatment of HER2-Positive Metastatic Breast Cancer

Denise A. YardleySarah Cannon Research Institute, Nashville, Tennessee, USA Tennessee Oncology, PLLC, Nashville, Tennessee, USA Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, USA Oncology Hematology Care, Cincinnati, Ohio, USA

Davey DanielSarah Cannon Research Institute, Nashville, Tennessee, USA Tennessee Oncology, PLLC, Nashville, Tennessee, USA Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, USA Oncology Hematology Care, Cincinnati, Ohio, USA

Michael StipanovSarah Cannon Research Institute, Nashville, Tennessee, USA Tennessee Oncology, PLLC, Nashville, Tennessee, USA Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, USA Oncology Hematology Care, Cincinnati, Ohio, USA

D. Randolph DrosickSarah Cannon Research Institute, Nashville, Tennessee, USA Tennessee Oncology, PLLC, Nashville, Tennessee, USA Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, USA Oncology Hematology Care, Cincinnati, Ohio, USA

Mark MainwaringSarah Cannon Research Institute, Nashville, Tennessee, USA Tennessee Oncology, PLLC, Nashville, Tennessee, USA Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, USA Oncology Hematology Care, Cincinnati, Ohio, USA

James PeytonSarah Cannon Research Institute, Nashville, Tennessee, USA Tennessee Oncology, PLLC, Nashville, Tennessee, USA Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, USA Oncology Hematology Care, Cincinnati, Ohio, USA

Mythili ShastrySarah Cannon Research Institute, Nashville, Tennessee, USA Tennessee Oncology, PLLC, Nashville, Tennessee, USA Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, USA Oncology Hematology Care, Cincinnati, Ohio, USA

John D. HainsworthSarah Cannon Research Institute, Nashville, Tennessee, USA Tennessee Oncology, PLLC, Nashville, Tennessee, USA Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, USA Oncology Hematology Care, Cincinnati, Ohio, USA

show all

ABSTRACT

We investigated the feasibility/efficacy of oxaliplatin in combination with trastuzumab as first-/second-line treatment of HER2-positive metastatic breast cancer (MBC). Patients received oxaliplatin/trastuzumab every 21 days and were evaluated every 6 weeks using RECIST criteria. The study closed early due to slow accrual. Twenty-five patients were evaluable; of these, 5 (20%) had objective responses to oxaliplatin/trastuzumab. Therapy was well tolerated (no grade-4 and gastrointestinal grade-3 toxicity in 4% of patients), but had only modest activity (median time-to-progression 1.8 months). Substitution of oxaliplatin for cisplatin or carboplatin, in combination with trastuzumab, does not appear to improve first-/second-line therapy in HER2-positive MBC.

Keywords :

Appendix—Sarah Cannon Research Consortium Participating Sites

Table

Download CSV Display Table

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

A Phase II Trial of Oxaliplatin and Trastuzumab in the Treatment of HER2-Positive Metastatic Breast Cancer

Information for

Open access

Opportunities

Help and information

A Phase II Trial of Oxaliplatin and Trastuzumab in the Treatment of HER2-Positive Metastatic Breast Cancer

ABSTRACT

Appendix—Sarah Cannon Research Consortium Participating Sites

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature